Impact of Estradiol on Endothelial Function in Peri-Menopausal Women

Status Recruiting

Clinical Trial Summary

The purpose of this study is to identify the impact of estradiol (E2) on the mechanisms that regulate vascular endothelial function in peri-menopausal (PERI) women. This study is the first step in understanding factors contributing to endothelial dysfunction in women with advancing reproductive age and in response to E2 administration.

Clinical Trial Description

Cardiovascular disease (CVD) is the leading cause of death in women. Although overall CVD-related mortality has declined, there has been an increase in CVD mortality in women aged 35-54 years, prior to menopause. It is unclear what contributes to this increased mortality rate, and is a significant problem for women's health. Endothelial function is considered a biomarker of cardiovascular health; declines in endothelial function are considered a precursor to the development of atherosclerosis and CVD. Thus, changes in endothelial function in women as they advance through reproductive stages towards menopause may play a role in the greater prevalence of CVD mortality. However, very few studies have focused on cardiovascular health in women leading up to menopause, during the PERI transition. The PERI period is a critical time point where reproductive hormones and ovarian function change rapidly. Recent data demonstrate that endothelial function begins to decline during PERI. Furthermore, despite women being of similar biological age, significant differences in endothelial function were noted when classified based on reproductive age - specifically between early PERI and late PERI. These data show that the decline initially occurs in the early PERI phase, making this a key time point for intervention to offset the future development of CVD. Our central hypothesis is that increased Endothelin-1 (ET-1) and a loss of Endothelin-1 B (ETB) mediated vasodilation play a primary role in contributing to impaired endothelial function with advancing reproductive age. We will assess macro- and micro- vascular endothelial function, assess intracellular ET-1 protein and ETB receptor expression in harvested endothelial cells from peripheral veins, and use the cutaneous circulation as an in vivo model to explore the receptor mechanisms (ETBR and ETAR) in early and late PERI in response to E2 or placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04255160
Study type	Interventional
Source	University of Delaware
Contact	Kathy Masso, BS
Phone	(302) 831-3493
Email	kcmasso@udel.edu
Status	Recruiting
Phase	Phase 4
Start date	October 1, 2020
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03680638` - The Effect of Antioxidants on Skin Blood Flow During Local Heating	Phase 1
Recruiting	`NCT05997732` - Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences	Phase 4
Recruiting	`NCT06117007` - Effects of Betalains on Cardiovascular Health and Quality of Life	N/A
Active, not recruiting	`NCT03659864` - The Role of Eicosanoids in the Cardiovascular Actions of Inhaled Nanoparticles	N/A
Completed	`NCT03459027` - Nitrate Supplementation and Muscle Blood Flow	N/A
Recruiting	`NCT05522075` - Reducing Blood Pressure in Mid-life Adult Binge Drinkers	N/A
Completed	`NCT00184886` - The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans	N/A
Completed	`NCT02095873` - Healthy Aging Through Functional Food	Phase 1/Phase 2
Completed	`NCT02292342` - An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men	Phase 0
Completed	`NCT00901745` - Interaction of Apelin and Angiotensin in the Human Forearm Circulation	N/A
Not yet recruiting	`NCT06290713` - Vasodilator and Exercise Study for DMD (VASO-REx)	Phase 2
Completed	`NCT02265107` - Effects of Exercise Training on Vascular Endothelial Function of Patients Submitted to Coronary Artery Bypass Graft	N/A
Recruiting	`NCT05219799` - Sex Disparities in Hypoxic Vasodilation and Impact of Obesity	Early Phase 1
Completed	`NCT03622060` - Intraarterial Nitroglycerin Versus Nicardipine and Radial Artery Occlusion	Phase 3
Completed	`NCT01618071` - Vascular Effects of Triglyceride-rich Lipoproteins	N/A
Completed	`NCT03190304` - The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure	Phase 4
Completed	`NCT04928183` - The Impact of Carbon Monoxide and Altitude on Vascular Function	N/A
Suspended	`NCT04001647` - Targeting ER Stress in Vascular Dysfunction	Early Phase 1
Completed	`NCT05525416` - Sex Differences in Sympathetic Vascular Reactivity at High Altitude	N/A
Completed	`NCT03605095` - Evidence of Spreading Vasodilation in Human Gingiva	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.